Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”

Detalles Bibliográficos
Autores principales: Chatelain, Pierre, Kjelgaard-Hansen, Mads, Sprogøe, Kennett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348463/
https://www.ncbi.nlm.nih.gov/pubmed/36869710
http://dx.doi.org/10.1210/clinem/dgad096
_version_ 1785073671502561280
author Chatelain, Pierre
Kjelgaard-Hansen, Mads
Sprogøe, Kennett
author_facet Chatelain, Pierre
Kjelgaard-Hansen, Mads
Sprogøe, Kennett
author_sort Chatelain, Pierre
collection PubMed
description
format Online
Article
Text
id pubmed-10348463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103484632023-07-15 Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial” Chatelain, Pierre Kjelgaard-Hansen, Mads Sprogøe, Kennett J Clin Endocrinol Metab Letter to the Editor Oxford University Press 2023-03-03 /pmc/articles/PMC10348463/ /pubmed/36869710 http://dx.doi.org/10.1210/clinem/dgad096 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Letter to the Editor
Chatelain, Pierre
Kjelgaard-Hansen, Mads
Sprogøe, Kennett
Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
title Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
title_full Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
title_fullStr Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
title_full_unstemmed Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
title_short Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
title_sort letter to the editor from chatelain et al: “weekly somapacitan is effective and well tolerated in children with gh deficiency: the randomized phase 3 real4 trial”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348463/
https://www.ncbi.nlm.nih.gov/pubmed/36869710
http://dx.doi.org/10.1210/clinem/dgad096
work_keys_str_mv AT chatelainpierre lettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial
AT kjelgaardhansenmads lettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial
AT sprogøekennett lettertotheeditorfromchatelainetalweeklysomapacitaniseffectiveandwelltoleratedinchildrenwithghdeficiencytherandomizedphase3real4trial

Ejemplares similares